Stempoint Capital LP Increases Stake in Assembly Biosciences, Inc. $ASMB

Stempoint Capital LP increased its stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 18.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 185,435 shares of the biopharmaceutical company’s stock after purchasing an additional 28,707 shares during the period. Stempoint Capital LP owned 1.17% of Assembly Biosciences worth $5,146,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Assembly Biosciences by 6.9% during the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 3,312 shares during the last quarter. Vanguard Group Inc. raised its stake in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Assembly Biosciences during the 3rd quarter worth about $485,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Assembly Biosciences during the 3rd quarter valued at about $3,120,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

ASMB opened at $25.11 on Thursday. The firm has a fifty day moving average price of $25.91 and a 200 day moving average price of $27.55. Assembly Biosciences, Inc. has a 1 year low of $16.90 and a 1 year high of $39.71. The stock has a market cap of $399.00 million, a P/E ratio of -228.25 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Equities analysts expect that Assembly Biosciences, Inc. will post 1.9 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ASMB shares. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Guggenheim reiterated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.